References
- Bossuyt PM, Reitsma JB, Bruns DE et al., STARD Group (2004). Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract, 21, 4-10. https://doi.org/10.1093/fampra/cmh103
- Calvo MS, Eyre DR, Gundberg CM (1996). Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev, 17, 333-68.
- Chung JH, Park MS, Kim YSet al. (2005). Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J, 46, 388-93. https://doi.org/10.3349/ymj.2005.46.3.388
- Demers LM, Costa L, Chinchilli VM et al. (1995). Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem, 41, 1489-94.
- Joerger M, Huober J (2012). Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res, 192, 197-223. https://doi.org/10.1007/978-3-642-21892-7_10
- Johansen JS, Brasso K, Iversen P et al. (2007). Changes of biochemical markers of bone turnover and YKL-40 following hormonaltreatment for metastatic prostate cancer are related to survival. Clin Cancer Res, 13, 3244-9. https://doi.org/10.1158/1078-0432.CCR-06-2616
- Jung K, Miller K, Wirth M et al. (2011). Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol, 59, 604-12. https://doi.org/10.1016/j.eururo.2010.12.006
- Kamby C, Egsmose C, Soletormos G, Dombernowsky P (1993). The diagnostic and prognostic value of serum bone GLA protein (osteocalcin) in patients with recurrent breast cancer. Scand J Clin Lab Invest, 53, 439-46. https://doi.org/10.3109/00365519309092538
- Kamiya N, Suzuki H, Endo T et al. (2012). Clinical usefulness of bone markers in prostate cancer with bone metastasis. Int J Urol, 10, 1442-2042
- Lacey DL, Timms E, Tan HL et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93, 165-76. https://doi.org/10.1016/S0092-8674(00)81569-X
- Lee JS, Tung CH (2011). Osteocalcin biomimic recognizes bone hydroxyapatite. Chembiochem, 12, 1669-73. https://doi.org/10.1002/cbic.201100162
- Lipton A, Costa L, Coleman RE (2011). Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates? Breast Dis, 33, 59-69.
- Meier C, Kraenzlin ME (2012). Osteoporosis: evaluation, diagnosis and monitoring. Ther Umsch, 69, 145-52. https://doi.org/10.1024/0040-5930/a000267
- Roodman GD (2012). Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev, 10, 10555-1112.
- Salem AM, Zohny SF, Abd El-Wahab MM, Hamdy R (2007). Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer. Clin Biochem, 40, 1201-8. https://doi.org/10.1016/j.clinbiochem.2007.07.006
- Simonet WS, Lacey DL, Dunstan CR, et al (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309-19. https://doi.org/10.1016/S0092-8674(00)80209-3
- Tamiya M, Suzuki H, Kobayashi M et al. (2011). Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer. Med Oncol, 29, 215-8.
- Yasuda H, Shima N, Nakagawa N et al. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin / osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA, 95, 3597-602. https://doi.org/10.1073/pnas.95.7.3597
Cited by
- Temporal Trends in the Inflammatory Cytokine Profile of Human Breastmilk vol.9, pp.10, 2014, https://doi.org/10.1089/bfm.2014.0043
- Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma vol.31, pp.8, 2016, https://doi.org/10.1111/jgh.13324